New head of Trajan Accelerator to drive longterm growth with start-ups

New head of Trajan Accelerator to drive longterm growth with start-ups

March 21, 2016

Trajan Scientific and Medical (Trajan) is pleased to announce the appointment of Elpis Barons as General Manager of the Trajan Accelerator. 

Conceived in late 2015, Trajan Accelerator provides a collaborative model targeting early stage enterprises sharing Trajan’s vision to positively impact human wellbeing through the application of science into society.

Ms Barons joins Trajan with extensive international business experience having nurtured her own business, Barons Medical Consulting since 2008 assisting international device manufactures and medical technology organizations through human clinical trials for the Australian market through strategic planning, sponsorship, clinical support and monitoring of the human clinical trials.

Her previous position in the UK with MedNova Ltd (acquired by Abbott Vascular) as the International Director of Sales and Marketing of emerging technologies for cardiovascular intervention, shows demonstrated success in the development and execution of human clinical trials, sales distribution and marketing.

Ms Baron’s passion for seeing the success of start-ups, combined with her knowledge of the clinical market and business acumen will ensure the Trajan Accelerator drives success and ensures we have a long and meaningful impact on human wellbeing across the globe.

The Trajan Accelerator model focuses on medtech companies with technologies, capabilities or markets that will contribute to improved wellbeing. Through financial and in kind support to facilitate growth, the Accelerator Company, and its staff then become part of the Trajan Group, while retaining a majority share and its identify.  Through accessing Trajan’s Corporate Services, the Accelerator Company is able to focus on their passion, while Trajan facilitates growth and whole business support through marketing, compliance, HR and global supply chain expertise etc.

Trajan’s active investment in the Accelerator program aims to help the start-up cross the “Valley of Death” and together build longterm sustainable businesses.


Photo (L-R): Elpis Barons, General Manager, Accelerator Group, Stephen Tomisich, Chief Executive Officer, Trajan Scientific and Medical.

Download
Trajan Press Release - International Media [PDF]
Trajan Press Release - Australian Media [PDF]

More information
Trajan Accelerator

Media contact information
media@trajanscimed.com
+61 (0) 3 9837 4200

PR Consultancy: LBPR
lisa@lbpr.com.au
+61 (0) 429 976 718




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More